NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Want to cut your energy bills? Here’s how five experts are doing it 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
DURHAM, N.C., Feb. 28, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
